Research programme: inflammatory therapeutics - Arcus Biosciences/Gilead Sciences
Latest Information Update: 28 May 2023
At a glance
- Originator Arcus Biosciences; Gilead Sciences
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Inflammation